Ajinomoto Bio-Pharma Services Completes Acquisition of Granules OmniChem Joint Venture in India
PR84228
WETTEREN, Belgium, June 2, 2020 /PRNewswire=KYODO JBN/ --
Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of
biopharmaceutical contract development and manufacturing services, is pleased
to announce that it has completed the acquisition of Granules OmniChem Private
Limited, purchasing the remaining 50 percent ownership interest from its joint
venture partner, Granules India Limited. The transaction, announced in August
2019, strengthens Aji Bio-Pharma's commitment to providing its clients
accessibility to a reliable and simplified CDMO supply chain across all sites
globally.
Logo - https://mma.prnewswire.com/media/751177/Aji_BioPharma_Logo.jpg
Now doing business as Ajinomoto Bio-Pharma Services India ("Aji Bio-Pharma
India"), the organization is fully integrated into Aji Bio-Pharma's global
operations. The Visakhapatnam, India site, which was designed, constructed and
is managed based on the Aji Bio-Pharma Belgian sites' GMP operating standards
and quality systems, has successfully supported a number of the world's leading
biopharmaceutical companies since its formation in 2011.
"The addition of Aji Bio-Pharma India is an integral extension of Aji
Bio-Pharma's dedication to its customers to be a leading global and
quality-driven CDMO with comprehensive service offerings," said David Enloe,
President and CEO, Ajinomoto Bio-Pharma Services. "We are excited to officially
welcome the Aji Bio-Pharma India team to our global family, and we look forward
to providing a further streamlined experience for our clients as they continue
to deepen their partnerships with us on essential programs in their product
pipeline."
"We are very pleased to be a part of a worldwide network committed to
simplifying our clients' supply chain," said K.V.V. Raju, CEO, Ajinomoto
Bio-Pharma India Pvt. Ltd. He further added, "As a fully integrated member of
Aji Bio-Pharma, we are committed to advancing Aji Bio-Pharma's Vision Statement
of being a leading, trusted, innovative partner to our clients and our people."
About Ajinomoto Bio-Pharma Services
Ajinomoto Bio-Pharma Services is a fully integrated contract development and
manufacturing organization with sites in Belgium, United States, Japan, and
India, providing comprehensive development, cGMP manufacturing, and aseptic
fill finish services for small and large molecule APIs and intermediates.
Ajinomoto Bio-Pharma Services offers a broad range of innovative platforms and
capabilities for pre-clinical and pilot programs to commercial quantities,
including Corynex(R) protein expression technology, oligonucleotide synthesis,
antibody drug conjugations (ADC), high potency APIs (HPAPI), biocatalysis,
continuous flow manufacturing and more. Ajinomoto Bio-Pharma Services is
dedicated to providing a high level of quality and service to meet our client's
needs. Learn more: www.AjiBio-Pharma.com
SOURCE: Ajinomoto Bio-Pharma Services
CONTACT: info@us.ajibio-pharma.com
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。